Deoxyribonucleic Acid (DNA) Vaccines Market is Expected to Grow with a 7.2% from 2021 to 2028

As stated in an extensive report, providing insights on Product Type and End User, the Global Market accounted for USD 4.55 Billion in 2021.

DNA vaccination refers to a technique for protecting an individual from disease by injecting it with genetically engineered DNA; cells directly produce an antigen which results in a protective immunological response. It consists of delivering fragments of it, encoding immunogenic antigens to host cells by using DNA plasmids as a vector.

DNA vaccines have a high potential of growth driven by increasing cases of cancer as well as infectious diseases in the animals and humans, coupled with the growth in demand for DNA vaccines because of the advantages it gives such as low stability at room temperature, and easy transportation. Additionally, the rise in the number of antibiotics resistant pathogens further propels the demand for DNA vaccines. The development of new vaccines utilizing DNA technology, along with huge growth potential in untapped budding economies is creating new opportunities for manufacturers to capitalize on the Market.

The COVID-19 pandemic has had a devastating global impact on the health of the population and a huge economic impact on most countries. Recently, DNA vaccines are on a trial basis for protecting against COVID1-19. In 2021, India has approved a new COVID-19 vaccine that uses circular strands of DNA to prime the immune system against the virus. Researchers have developed the first DNA vaccine for people to receive approval anywhere in the world. Zyvox-D (DNA vaccine), which is administered into the skin without an injection, has been found to be 67% protective against symptomatic COVID-19 in clinical trials, and will probably start to be administered in India in the coming months. Hence in the coming years, the DNA vaccine might prove beneficial for the COVID-19 virus crisis and is expected to generate revenue from the market.

The development in molecular biology & immunology is one of the factors intensifying the market growth. The increasing cases of cancer, hepatitis, HIV, and others coupled with the increase in government interest with investment in DNA vaccines are some other growth factors. The surge in the number of antibiotics resistant pathogens has magnified the need for low-cost and effective vaccination, acting as significant driving factors for this market.

North America is projected to witness substantial growth in coming years owing to the DNA vaccine such as Apex-IHN and Oncept vaccines, to treat animal diseases has got approval in Canada, and the 160; in the region. 10;is about to cover a higher market share in the DNA vaccine market driven by the presence of well-established veterinary organizational structures coupled with DNA vaccine approval in the country and high buying power.

Some of the prominent players operating in the Market include, Inovio Biomedical Corp, Merck & Co., Mitsubishi Tanabe, Dendreon Corporation, ASTELLAS PHARMA, Dynavax Technologies, Sanofi, Tekmira Pharmaceuticals GlaxoSmithKline Corp, Protein Sciences others